Moleculin Strengthens Its Patent Portfolio for Annamycin
The company expands its global intellectual property coverage, prolonging claims to vital markets until June 2040.
HOUSTON – Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical firm focused on delivering innovative drug candidates for challenging cancers and viral infections, has announced that it has successfully obtained two new U.S. patents for Annamycin from the U.S. Patent and Trademark Office. These patents, numbered 12,257,261 and 12,257,262, are centered around the preparation and reconstitution of liposomal Annamycin, an exciting novel drug candidate.
The first patent, 12,257,261, describes methods for preparing the liposomal Annamycin lyophilizate, while the second, 12,257,262, details the processes involved in creating a liposomal suspension. The protection offered by these patents extends until June 2040 and is subject to adjustments for any delays in regulatory approval processes.
Currently in the clinical stage, Annamycin is being developed as the first anthracycline with a purported absence of associated cardiotoxicity. This treatment is geared towards patients suffering from acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets). Recent preclinical studies conducted at a prestigious cancer research center also suggest Annamycin's potential efficacy in treating various cancer types.
The Vision for Annamycin’s Development
Wally Klemp, the Chairman and CEO of Moleculin, expressed enthusiasm regarding the expansion of the company’s intellectual property as it relates to Annamycin. He noted that with the addition of these new patents, Moleculin now holds a total of four U.S. patents connected to Annamycin, complementing existing patents granted in Europe. Klemp emphasized the company's commitment to this essential treatment option as they continue to advance in their pivotal, adaptive Phase 3 MIRACLE clinical trial, with initial results anticipated in the latter half of the year 2025.
Importantly, Annamycin has received both Fast Track Status and Orphan Drug Designation from the FDA for treating relapsed or refractory AML, alongside Orphan Drug Designation for the treatment of STS lung mets. The European Medicines Agency (EMA) has also granted Orphan Drug Designation for Annamycin in treating relapsed or refractory AML, evidencing the global recognition of its therapeutic value.
Understanding Moleculin Biotech’s Mission
Moleculin Biotech, Inc. is dedicated to addressing serious global health issues through its innovative clinical solutions targeting difficult-to-treat tumors and viral diseases. The flagship program Annamycin is designed to overcome the limitations of existing anthracyclines by eliminating the cardiotoxicity that is typically encountered with these drugs. Ongoing discussions surrounding Annamycin's innovative design highlight its potential to revolutionize treatment for patients battling AML and STS lung metastases.
The company is progressing with the MIRACLE Trial (Moleculin R/R AML AnnAraC Clinical Evaluation), an adaptive design Phase 3 study evaluating the combination of Annamycin and cytarabine, collectively referred to as AnnAraC. Following positive outcomes from the Phase 1B/2 study (MB-106) and supportive feedback from the FDA, Moleculin is confident about its pathway to potential approval for Annamycin in treating AML.
Innovating Beyond Annamycin
In addition to Annamycin, Moleculin is actively developing WP1066, a promising Immune/Transcription Modulator with the capability to inhibit oncogenic transcription factors while stimulating natural immune responses, specifically targeting brain tumors and pancreatic cancer. The company is also investing in a variety of antimetabolites, including WP1122, which shows potential in treating viral pathogens alongside specified cancer indications.
Investing in Future Possibilities
Moleculin is committed to making strides in the competitive landscape of pharmaceuticals, especially in addressing unmet medical needs through innovative therapeutics. The granting of these new patents not only ensures exclusivity over Annamycin but also positions Moleculin as a forefront leader in oncological and viral treatments. With a robust patent portfolio and promising clinical data, the company is poised to influence the realm of cancer treatment significantly.
Frequently Asked Questions
What new patents has Moleculin received?
Moleculin received two new U.S. patents related to Annamycin, focusing on preparation and reconstitution methods for the liposomal form of the drug.
What is Annamycin used for?
Annamycin is being developed as a treatment for acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.
What is the MIRACLE trial?
The MIRACLE trial is a Phase 3 clinical trial evaluating the safety and efficacy of Annamycin in combination with cytarabine for treating relapsed or refractory AML.
What designations has Annamycin received from regulatory bodies?
Annamycin has Fast Track Status and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation from the EMA for AML treatments.
What other drugs is Moleculin developing?
Moleculin is also developing WP1066, an Immune/Transcription Modulator, and WP1122, aimed at treating pathogenic viruses and certain cancers.
